Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis
ClinicalTrials.gov Identifier:
NCT01127750
First received: May 19, 2010
Last updated: January 18, 2012
Last verified: January 2012
  Purpose

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.


Condition Intervention Phase
Relapsing Multiple Sclerosis
Drug: FTY720
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 4-month, Open-label, Multi-center Study to Explore Tolerability and Safety and Health Outcomes of FTY720 in Patients With Relapsing Forms of Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Evaluate the safety and tolerability profile of FTY720 in patients with relapsing forms of MS [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Incidence of macular edema [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
  • Incidence of bradyarrhythmic electrocardiograms (ECGs) [ Time Frame: 4 months ] [ Designated as safety issue: Yes ]
  • Patient reported outcomes indices in multiple sclerosis (PRIMUS), short form health survey-12, and treatment satisfaction questionnaire for medication (TSQM-9) [ Time Frame: 4 months ] [ Designated as safety issue: No ]

Enrollment: 2417
Study Start Date: May 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FTY720 Drug: FTY720

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-65 years of age, must have relapsing MS

Exclusion Criteria:

  • Patients with a type of MS that is not relapsing
  • Patients with history of chronic immune disease
  • Patients with a history of certain cancers
  • Diabetic patients with certain eye disorders
  • Patients who are on certain immunosuppressive medications or heart medications
  • Patients with certain heart conditions
  • Patients with certain lung conditions

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01127750

  Hide Study Locations
Locations
Australia
Novartis Investigative Site
Box Hill, Australia, 3128
Novartis Investigative Site
Heidelberg, Australia, 3084
Novartis Investigative Site
Kogarah, Australia, 2217
Novartis Investigative Site
Liverpool, Australia, 2170
Novartis Investigative Site
Woodville South, Australia, 5011
Austria
Novartis Investigational Site
Linz, Austria, A-4020
Novartis Investigational Site
Vienna, Austria, 1090
Novartis Investigational Site
Vienna, Austria, 1010
Belgium
Novartis Investigational Site
Brugge, Belgium, 8000
Novartis Investigational Site
Bruxelles, Belgium, 1200
Novartis Investigational Site
Bruxelles, Belgium, 1070
Novartis Investigational Site
Charleroi, Belgium, 6000
Novartis Investigational Site
Leuven, Belgium, 3000
Novartis Investigational Site
Melsbroek, Belgium, 1820
Novartis Investigational Site
Overpelt, Belgium, 3900
Novartis Investigational Site
Sijsele, Belgium, 8340
Novartis Investigational Site
Tinlot, Belgium, 4557
Novartis Investigational Site
Wilrijk, Belgium, 2610
Canada
Novartis Investigational Site
Montreal, Canada, H2L 4M1
Novartis Investigational Site
Quebec, Canada, G1J 1Z4
Novartis Investigational Site
Victoria, Canada, V8R 1J8
Czech Republic
Novartis Investigational Site
Praha 2, Czech Republic, 128 02
Novartis Investigational Site
Teplice, Czech Republic, 415 29
Denmark
Novartis Investigational Site
Copenhagen, Denmark, 2100
Novartis Investigational Site
Århus, Denmark, DK-8000
Finland
Novartis Investigational Site
Helsinki, Finland, 00100
Novartis Investigational Site
Turku, Finland, 20520
Germany
Novartis Investigative Site
Aachen, Germany, 52062
Novartis Investigational Site
Aachen, Germany, 52062
Novartis Investigational Site
Aalen, Germany, 73430
Novartis Investigational Site
Abensberg, Germany, 93326
Novartis Investigational Site
Achim, Germany, 28832
Novartis Investigational Site
Alzenau, Germany, 63755
Novartis Investigational Site
Aschaffenburg, Germany, 63739
Novartis Investigational Site
Attenberg, Germany, 04600
Novartis Investigational Site
Augsburg, Germany, 86156
Novartis Investigational Site
Bad Honnef, Germany, 53604
Novartis Investigational Site
Bad Krozingen, Germany, 79189
Novartis Investigative Site
Bad Mergentheim, Germany, 97980
Novartis Investigational Site
Bad Neustadt / Saale, Germany, 97616
Novartis Investigational Site
Bamberg, Germany, 96047
Novartis Investigational Site
Bamberg, Germany, 96049
Novartis Investigative Site
Bayreuth, Germany, 95445
Novartis Investigative Site
Berlin, Germany, 13507
Novartis Investigative Site
Berlin, Germany, 13439
Novartis Investigative Site
Berlin, Germany, 10961
Novartis Investigative Site
Berlin, Germany, 10117
Novarris Investigative Site
Berlin, Germany, 13088
Novartis Investigative Site
Berlin, Germany, 10713
Novartis Investigative Site
Berlin, Germany, 10625
Novartis Investigative Site
Berlin, Germany, 14163
Novartis Investigative Site
Berlin, Germany, 12163
Novartis Investigative Site
Berlin, Germany, 13347
Novartis Investigative Site
Berlin, Germany, 10785
Novartis Investigative Site
Berlin, Germany, 12103
Novartis Investigative Site
Berlin, Germany, 10178
Novartis Investigative Site
Berlin, Germany, 12351
Novartis Investigative Site
Bielefeld, Germany, 33647
Novartis Investigative Site
Bielefeld, Germany, 33602
Novartis Investigative Site
Bielefeld, Germany, 33617
Novartis Investigative Site
Boblingen, Germany, 71034
Novartis Investigational Site
Bochum, Germany, 44791
Novartis Investigative Site
Bochum, Germany, 44789
Novaratis Investigative Site
Bochum, Germany, 44892
Novartis Investigational Site
Bochum, Germany, 44787
Novartis Investigational Site
Bogen, Germany, 94327
Novartis Investigative Site
Bonn, Germany, 53105
Novartis Investigative Site
Bonn, Germany, 53117
Novartis Investigational Site
Braunschweig, Germany, 38126
Novartis Investigational Site
Buchholz, Germany, 21244
Novartis Investigational Site
Chemnitz, Germany, 09117
Novartis Investigational Site
Dillingen, Germany, 89407
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Düsseldorf, Germany, 40211
Novartis Investigational Site
Eisenach, Germany, 99817
Novartis Investigative Site
Emden, Germany, 26721
Novartis Investigational Site
Emmendingen, Germany, 79312
Novartis Investigative Site
Erbach, Germany, 64711
Novartis Investigational Site
Erfurt, Germany, 99089
Novartis Investigational Site
Erlangen, Germany, 91054
Novartis Investigative Site
Essen, Germany, 103949
Novartis Investigative Site
Essen, Germany, 45138
Novartis Investigational Site
Essen, Germany, 45131
Novartis Investigational Site
Frankfurt, Germany, 60488
Novartis Investigational Site
Frankfurt, Germany, 60528
Novartis Investigative Site
Freiburg, Germany, 79106
Novartis Investigational Site
Greifswald, Germany, 17487
Novartis Investigational Site
Grevenbroich, Germany, 41515
Novartis Investigational Site
Hamburg, Germany, 22087
Novartis Investigative Site
Hamburg, Germany, 20249
Novartis Investigative Site
Hamburg, Germany, 22083
Novartis Investigative Site
Hamburg, Germany, 20099
Novartis Investigative Site
Hamburg, Germany, 22179
Novartis Investigative Site
Hamburg, Germany, 20354
Novartis Investigative Site
Hamburg, Germany, 22523
Novartis Investigative Site
Hamburg, Germany, 22297
Novartis Investigational Site
Hamburg, Germany, 22291
Novartis Investigative Site
Hannover, Germany, 30625
Novartis Investigative Site
Hannover, Germany, 30161
Novartis Investigative Site
Hannover, Germany, 30559
Novartis Investigative Site
Heidelburg, Germany, 69120
Novartis Investigational Site
Herborn, Germany, 35745
Novartis Investigational Site
Herdecke, Germany, 58313
Novartis Investigational Site
Herne, Germany, 44651
Novartis Investigational Site
Homburg, Germany, 66421
Novartis Investigational Site
Itzehoe, Germany, 25524
Novartis Investigational Site
Jena, Germany, 07743
Novartis Investigational Site
Jena, Germany, 07740
Novartis Investigational Site
Kaltenkirchen, Germany, 24568
Novartis Investigative Site
Kandel, Germany, 76870
Novartis Investigational Site
Karlsruhe, Germany, 76133
Novartis Investigational Site
Karlstadt, Germany, 97753
Novartis Investigational Site
Kassel, Germany, 34121
Novartis Investigative Site
Koeln, Germany, 51109
Novartis Investigative Site
Koln, Germany, 50924
Novartis Investigative Site
Koln, Germany, 50935
Neuroscience Research of the Berkshires
Krefeld, Germany, 47805
Novartis Investigational Site
Landshut, Germany, 84028
Novartis Investigational Site
Lappersdorf, Germany, 93138
Novartis Investigational Site
Leipzig, Germany, 04275
Novartis Investigative Site
Lengerich, Germany, 49525
Novartis Investigational Site
Lohr am Main, Germany, 79816
Novartis Investigative Site
Ludwigshafen, Germany, 67063
Novartis Investigational Site
Ludwigshafen, Germany, 67059
Novartis Investigative Site
Magdeburg, Germany, 39120
Novartis Investigative Site
Mainz, Germany, 55101
Novartis Investigational Site
Mannheim, Germany, 68159
Novartis Investigational Site
Marburg, Germany, 35039
Novartis Investigational Site
Marburg, Germany, 35033
Novartis Investigational Site
Mittweida, Germany, 09648
Novartis Investigational Site
Muenchen, Germany, 80331
Novartis Investigational Site
Muenchen, Germany, 81377
Novartis Investigational Site
Muenster, Germany, 48149
Novartis Investigational Site
Munchen, Germany, 81829
Novartis Investigational Site
Mönchengladbach, Germany, 41063
Novartis Investigative Site
München, Germany, 81825
Novartis Investigational Site
München, Germany, 81675
Novartis Investigational Site
München, Germany, 81241
Novartis Investigational Site
Nagold, Germany, 72202
Novartis Investigational Site
Neu-Ulm, Germany, 89231
Novartis Investigational Site
Neuburg, Germany, 86633
Novartis Investigational Site
Neuruppin, Germany, 16816
Novartis Investigational Site
Nurnberg, Germany, 90461
Novartis Investigative Site
Oldenburg, Germany, 26122
Novartis Investigational Site
Osnabrück, Germany, 49076
Novartis Investigational Site
Ostfildern, Germany, 73760
Novartis Investigational Site
Pforzheim, Germany, 75172
Novartis Investigational Site
Potsdam, Germany, 14467
Novartis Investigational Site
Potsdam, Germany, 14471
Novartis Investigational Site
Prien, Germany, 83209
Novartis Investigational Site
Regensburg, Germany, 93053
Novartis Investigational Site
Rostock, Germany, 18147
Novartis Investigative Site
Rudersdorf, Germany, 15562
Novartis Investigational Site
Rösrath, Germany, 51503
Novartis Investigational Site
Schwarzenbruck, Germany, 90592
Novartis Investigative Site
Schwendi, Germany, 88477
Novartis Investigative Site
Siegen, Germany, 57072
Novartis Investigational Site
Sigmaringen, Germany, 72488
Novartis Investigational Site
Sinsheim, Germany, 74889
Novartis Investigative Site
Stade, Germany, 21682
Novartis Investigative Site
Stuttgart, Germany, 70182
Novartis Investigative Site
Stuttgart, Germany, 70178
Novartis Investigational Site
Stuttgart, Germany, 70191
Novartis Investigational Site
Stuttgart, Germany, 70176
Novartis Investigational Site
Teupitz, Germany, 15755
Novartis Investigational Site
Tübingen, Germany, 72076
Novartis Investigative Site
Ulm, Germany, 89073
Novartis Investigational Site
Unterhaching, Germany, 82008
Novartis Investigational Site
Wendlingen, Germany, 73240
Novartis Investigational Site
Wermsdorf, Germany, 04779
Novartis Investigational Site
Westerstede, Germany, 26655
Novartis Investigative Site
Wiesbaden, Germany, 65191
Novartis Investigational Site
Wiesbaden, Germany, 65183
Novartis Investigational Site
Wuppertal, Germany, 42283
Novartis Investigational Site
Würzburg, Germany, 97080
Greece
Novartis Investigational Site
Alexandroupolis, Greece, 68100
Novartis Investigational Site
Athens, Greece, 10675
Novartis Investigational Site
Athens, Greece, 15123
Novartis Investigational Site
Thessaloniki, Greece, GR 570 10
Novartis Investigational Site
Thessaloniki, Greece, 57001
Hungary
Novartis Investigational Site
Budapest, Hungary, 1083
Novartis Investigational Site
Budapest, Hungary, 1204
Novartis Investigational Site
Budapest, Hungary, 1115
Novartis Investigational Site
Pecs, Hungary, 7623
Novartis Investigational Site
Szeged, Hungary, H-6725
Ireland
Novartis Investigational Site
Cork, Ireland
Novartis Investigational Site
Dublin 4, Ireland
Novartis Investigational Site
Dublin 9, Ireland
Italy
Novartis Investigative Site
Acquaviva delle Fonti, Italy, 70021
Novartis Investigative SIte
Asti, Italy, 14100
Novartis Investigative Site
Bergamo, Italy, 24128
Novartis Investigative Site
Bologna, Italy, 40139
Novartis Investigative Site
Cagliari, Italy, 09126
Novartis Investigative Site
Catania, Italy, 95122
Novartis Investigative Site
Foggia, Italy, 71100
Novartis Investigational Site
Foggia, Italy, 71100
Novartis Investigative Site
Milano, Italy, 20132
Novartis Investigative Site
Napoli, Italy, 80131
Novartis Investigational Site
Napoli, Italy, 80138
Novartis Investigational Site
Napoli, Italy, 80132
Novartis Investigative Site
Palermo, Italy, 90146
Novartis Investigative Site
Pozzilli, Italy, 86077
Novartis Investigative Site
Ravenna, Italy, 48100
Novartis Investigational Site
Roma, Italy, 00168
Novartis Investigational Site
Roma, Italy, 00135
Novartis Investigational Site
Roma, Italy, 00185
Novartis Investigational Site
Roma, Italy, 00161
Novartis Investigative Site
Siena, Italy, 53100
Novartis Investigative Site
Udine, Italy, 33100
Novartis Investigative Site
Verona, Italy, 37134
Novartis Investigative Site
Vicenza, Italy, 36100
Novartis Investigative Site
Viterbo, Italy, 01100
Netherlands
Novartis Investigational Site
Amsterdam, Netherlands, 1081 HV
Novartis Investigational Site
Amsterdam, Netherlands, 1061 AE
Novartis Investigational Site
Blaricum, Netherlands, 1261 AN
Novartis Investigational Site
Breda, Netherlands, 4818 CK
Novartis Investigational Site
Enschede, Netherlands, 7513 ER
Novartis Investigational Site
Gouda, Netherlands, 2800 BB
Novartis Investigational Site
Tilburg, Netherlands, 5022 GC
Norway
Novartis Investigational Site
Lillehammer, Norway, 2609
Novartis Investigational Site
Molde, Norway, 6407
Novartis Investigational Site
Stavanger, Norway, 4868
Poland
Novartis Investigational Site
Bydgoszcz, Poland, 85-681
Novartis Investigational Site
Katowice, Poland, 40-594
Novartis Investigational Site
Lodz, Poland, 90-153
Portugal
Novartis Investigational Site
Amadora, Portugal, 2720-276
Novartis Investigational Site
Coimbra, Portugal, 3041-853
Novartis Investigational Site
Lisboa, Portugal, 1649-035
Novartis Investigational Site
Porto, Portugal, 4200-319
Novartis Investigational Site
Porto, Portugal, 4099-001
Russian Federation
Novartis Investigational Site
Ekaterinburg, Russian Federation, 620102
Novartis Investigational Site
Kazan, Russian Federation, 420021
Novartis Investigational Site
Kazan, Russian Federation, 420097
Novartis Investigational Site
Moscow, Russian Federation, 127018
Novartis Investigational Site
Moscow, Russian Federation, 121356
Novartis Investigational Site
Moscow, Russian Federation, 125367
Novartis Investigational Site
Nizhny Novgorod, Russian Federation, 603018
Novartis Investigational Site
Nizhny Novgorod, Russian Federation, 603155
Novartis Investigational Site
S.-Petersburg, Russian Federation, 194044
Novartis Investigational Site
Samara, Russian Federation, 443095
Novartis Investigational Site
Smolensk, Russian Federation, 214019
Novartis Investigational Site
St. Petersburg, Russian Federation, 197376
Slovakia
Novartis Investigational Site
Banska Bystrica, Slovakia, 975 17
Novartis Investigational Site
Bratislava, Slovakia, 82606
Novartis Investigational Site
Trnava, Slovakia, 917 75
Spain
Novartis Investigational Site
Barcelona, Spain, 08036
Novartis Investigational Site
Barcelona, Spain, 08025
Novartis Investigational Site
El Palmar, Spain, 30120
Novartis Investigational Site
Madrid, Spain, 28034
Novartis Investigational Site
Madrid, Spain
Novartis Investigational Site
San Sebastian, Spain, 20014
Novartis Investigational Site
Santa Cruz de Tenerife, Spain, 38009
Novartis Investigational Site
Santiago de Compostela, Spain, 15706
Novartis Investigational Site
Valencia, Spain, 46010
Sweden
Novartis Investigational Site
Göteborg, Sweden, 413 45
Novartis Investigational Site
Linköping, Sweden, 581 85
Novartis Investigational Site
Umea, Sweden, 901 85
Switzerland
Novartis Investigational Site
Aarau, Switzerland, 5001
Novartis Investigational Site
Carouge, Switzerland, 1227
Novartis Investigational Site
Geneve, Switzerland, 1211
Novartis Investigational Site
Lausanne, Switzerland, 1011
Novartis Investigational Site
Lugano, Switzerland, 6900
Novartis Investigational Site
St. Gallen, Switzerland, 9007
Novartis Investigational Site
Zuerich, Switzerland, 8091
Turkey
Novartis Investigational Site
Antalya, Turkey, 07070
Novartis Investigational Site
Gaziantep, Turkey, 27070
Novartis Investigational Site
Istanbul, Turkey, 34098
Novartis Investigational Site
Istanbul, Turkey, 34096
Novartis Investigational Site
Samsun, Turkey
Novartis Investigational Site
Trabzon, Turkey, 61080
United Kingdom
Novartis Investigational Site
Birmingham, United Kingdom, B15 2TH
Novartis Investigational Site
Brighton, United Kingdom, BN2 2BE
Novartis Investigational Site
Dundee, United Kingdom
Novartis Investigational Site
Edinburgh, United Kingdom, EH4 2XU
Novartis Investigational Site
Essex, United Kingdom, RM7 0BE
Novartis Investigational Site
Great Yarmouth, United Kingdom, NR31 6LA
Novartis Investigational Site
Headington, United Kingdom, OX3 9DU
Novartis Investigational Site
Liverpool, United Kingdom, L9 7LJ
Novartis Investigational Site
London, United Kingdom, W8 6RF
Novartis Investigational Site
London, United Kingdom, SW17 0QT
Novartis Investigational Site
Middlesborough, United Kingdom, TS4 3BW
Novartis Investigational Site
Newcastle Upon Tyne, United Kingdom, NE1 4LP
Novartis Investigational Site
Northampton, United Kingdom, NN1 5BD
Novartis Investigational Site
Norwick, United Kingdom, NR4 7UY
Novartis Investigational Site
Poole, United Kingdom, BH15 2JB
Novartis Investigational Site
Salford, United Kingdom, M6 8HD
Novartis Investigational Site
Sheffield, United Kingdom, S10 2JF
Novartis Investigational Site
Stoke on Trent, United Kingdom, ST4 6QG
Novartis Investigational Site
Swindon, United Kingdom, SN3 6BB
Novartis Investigational Site
Truro, United Kingdom, TR1 3LJ
Sponsors and Collaborators
Novartis
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis
ClinicalTrials.gov Identifier: NCT01127750     History of Changes
Other Study ID Numbers: CFTY720D2316, 2010-019029-32
Study First Received: May 19, 2010
Last Updated: January 18, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Novartis:
Relapsing multiple sclerosis
MS
safety
tolerability
health outcomes

Additional relevant MeSH terms:
Multiple Sclerosis
Sclerosis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Fingolimod
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 28, 2014